Objective: Mesial temporal lobe epilepsy (mTLE) is a severe neurological disorder characterized by recurrent seizures. mTLE is frequently accompanied by neurodegeneration in the hippocampus resulting in hippocampal sclerosis (HS), the most common morphological correlate of drug resistance in mTLE patients. Incomplete knowledge of pathological changes in mTLE+HS complicates its therapy. The pathological mechanism underlying mTLE+HS may involve abnormal gene expression regulation, including posttranscriptional networks involving microRNAs (miRNAs). miRNA expression deregulation has been reported in various disorders, including epilepsy. However, the miRNA profile of mTLE+HS is not completely known and needs to be addressed. Methods: Here, we have focused on hippocampal miRNA profiling in 33 mTLE+HS patients and nine postmortem controls to reveal abnormally expressed miRNAs. In this study, we significantly reduced technology-related bias (the most common source of false positivity in miRNA profiling data) by combining two different miRNA profiling methods, namely next generation sequencing and miRNA-specific quantitative realtime polymerase chain reaction. Results: These methods combined have identified and validated 20 miRNAs with altered expression in the human epileptic hippocampus; 19 miRNAs were up-regulated and one down-regulated in mTLE+HS patients. Nine of these miRNAs have not been previously associated with epilepsy, and 19 aberrantly expressed miRNAs potentially regulate the targets and pathways linked with epilepsy (such as potassium channels, c-aminobutyric acid, neurotrophin signaling, and axon guidance). Significance: This study extends current knowledge of miRNA-mediated gene expression regulation in mTLE+HS by identifying miRNAs with altered expression in mTLE+HS, including nine novel abnormally expressed miRNAs and their putative targets. These observations further encourage the potential of microRNA-based biomarkers or therapies.
Temporal lobe epilepsy (TLE) is a neurological disorder characterized by recurrent seizures originating in the temporal cortical structures. TLE is a common epilepsy type accounting for one-third of all diagnosed epileptic patients. TLE can be divided into several subgroups, including the most prevalent mesial TLE (mTLE). mTLE is associated with frequent hippocampal sclerosis (HS) occurrence and a remarkable risk of resistance to a broad range of antiepileptic drugs. 1, 2 Because the underlying pathogenic mechanism of mTLE+HS is still not completely understood, the therapy is considerably complicated. Exploring the markers of pathological changes in mTLE+HS, such as aberrant micro-RNA (miRNA) profiles, may provide better insight into the biological processes of mTLE+HS and could be potentially utilized in miRNA-based therapies.
miRNAs are small endogenous noncoding RNAs critical for the post-transcriptional regulation of the vast majority of mRNAs.
3 miRNA biogenesis is a conserved process, which results in 21-25-nucleotide-long products regulating gene expression by complementary binding to the target mRNA. 4 Due to the miRNAs' regulatory function, their dynamic balance is essential for the normal development and function of the human brain, and their imbalance may introduce various neuropathologies. 5, 6 Since 2010, numerous studies on epilepsy have provided plausible evidence that miRNAs play a role in the pathogenesis of this disease. Nevertheless, most of these studies employed animal models of epilepsy, whereas only relatively few have addressed miRNA expression profiles in human brain tissue (reviewed in Alsharafi et al. 7 ). In this study, we describe miRNA expression patterns in the hippocampus detected on a cohort of well-characterized samples from 33 mTLE+HS patients compared with control hippocampal tissues. To the best of our knowledge, this study of miRNA expression has been performed on the largest cohort of human mTLE+HS patients yet. We employed a combination of cutting-edge technologies, namely next generation sequencing (NGS) and miRNA-specific quantitative real-time polymerase chain reaction (miQPCR), to acquire high precision, specificity, and access to miRNAs not included in commercial profiling panels. 8 Our study revealed the correlation of both methods in the miRNA profiling of brain tissues and discovered new aberrantly expressed miRNAs and their predicted targets (genes and biological pathways) in mTLE+HS.
Methods

Patient cohorts
The analysis of the hippocampal tissue was performed on a cohort of anteromesial temporal resections at St. Anne's University Hospital in Brno, Czech Republic within the period 2007-2016. We studied 19 patients with left-sided mTLE (10 women, nine men) and 14 patients with right-sided mTLE (six women, eight men). All patients were referred to the Department of Neurology at Brno Epilepsy Center for their medical intractability and fulfilled the diagnostic criteria for mTLE+HS. The diagnosis was made according to the International League Against Epilepsy (ILAE) criteria (Commission on Classification and Terminology of ILAE, 1989) . Visual inspections of the magnetic resonance imaging (MRI) scans (the MRI protocol included T 1 , T 2 , and fluid-attenuated inversion recovery sequences [axial and coronal slices]) by two independent physicians (radiologist and epileptologist) revealed unilateral HS concordant with the electroencephalographic lateralization of the epileptogenic zone in all patients. None of the patients revealed other brain structural lesions on MRI scans or had undergone previous intracranial surgery. The average age of the patients at the time of surgery was 38.4 years (range = 17-59), and the mean disease duration was 22.7 years (range = 1-58). Paraffin-embedded control hippocampal tissue samples were obtained from nine postmortem cases without hippocampal aberrations from the Department of Forensic Medicine at St. Anne's University Hospital. The average age of controls at the time of death was 58 years (range = 30-77). A detailed overview of patients and postmortem controls is listed in Table S1 . All patients have approved the use of their tissue for scientific purposes particularly in this study by signing informed consent. All procedures to obtain hippocampal control tissue samples were in accordance with the Czech Republic's legislation and ethical standards and with the 1964 Helsinki declaration (revised in 2013). Brain tissues were postsurgically stored in paraffin at the First Department of Pathological Anatomy of St. Anne's University Hospital in Brno. This study was approved by the Ethical Committee of St. Anne's University Hospital in Brno (approval number 9G/2015-KS).
Tissue processing
Surgically resected and autopsy tissues were identically treated; they were fixed in 10% neutral buffered formalin, grossly inspected, and carefully oriented, and their proportions were measured. Hippocampal specimens were dissected into 2-3-mm-thick tissue slices along the anterior-posterior axis. Representative tissue samples were routinely processed and paraffin embedded. Formalinfixed paraffin-embedded (FFPE) tissue sections were stained with hematoxylin-eosin and evaluated using light microscopy. The presence of neuronal depletion and gliosis in HS tissue samples was confirmed using neuronal nuclei and glial fibrillary acidic protein immunohistochemistry. The ILAE classification criteria 9 for HS were applied. For miRNA analysis, paraffin-embedded tissue slices showing the presence of hippocampal complex were selected.
Total RNA isolation
Total RNA was isolated from FFPE tissue sections using the High Pure miRNA Isolation Kit (Roche) according to the manufacturer's protocol. To obtain increased RNA yields, overnight proteinase K digestion was used. RNA was successfully extracted from all specimens and quantified using NanoDrop ND-1000 (Thermo Fisher Scientific). The 1.1 lg of extracted total RNA was used to prepare small RNA libraries and sequenced on NextSeq 500 (Illumina); the remaining RNA underwent specific reverse transcription for miQPCR analysis.
Preparing and sequencing of NGS libraries
Libraries for sequencing were prepared from 1.1 lg of total RNA obtained from 16 randomly selected mTLE+HS patients who underwent resection in the time period 2007-2012 and eight postmortem controls, with a sufficient concentration and quality of isolated total RNA. Libraries were prepared using a NEXTflex Small RNASeq Kit v2 (Bioo Scientific) according to the manufacturer's protocol. Size selection on 6% polyacrylamide gel was performed for each library prior to sequencing. cDNA fragments were separated on a gel for 1 h at 90 V, stained with ethidium bromide, and visualized using an ultraviolet transilluminator. The 150-bp-long fragments representing the length of mature miRNA with adaptors and barcode sequences were cut out and eluted into 10 mM Tris-HCl buffer at pH 8.5. After removing gel residues by filtration, the libraries were quantified using NanoDrop ND-1000 and used for sequencing on NextSeq 500 according to the manufacturer's protocol.
NGS data processing and differential expression analysis of miRNAs
Count-based miRNA expression data were generated by the Chimira 10 tool from FASTQ files. All sequences were adapter trimmed and mapped against miRBase v21 allowing up to two mismatches per sequence. Further analyses were performed using R/Bioconductor packages. 11 Differential expression analysis was performed by two approaches. At first, raw reads were analyzed by DESeq2 method. 12 Second, read counts were prenormalized by adding normalization factors within the edgeR package 13 and further between-sample normalized by the voom function in the limma package.
14 These packages mainly differ in the estimation of the dispersion parameter and the type of normalization they follow. DESeq2 bases the estimation of the dispersion on calculated mean-variance relationships in the dataset provided, whereas edgeR assumes a common dispersion for all the genes. The differentially expressed miRNAs were screened out between patients' and control samples applying linear model fitting and eBayes approach. Briefly, eBayes function use linear fitting of individual genes to build a hierarchical Bayes model, which estimates the probability of their differential expressions. It uses data-defined global priors to shrink the sample variances toward a common value and, therefore, enhance the statistical power and accuracy. The obtained probability values were adjusted for multiple testing using the Benjamini-Hochberg method. Raw data and annotated sequences of the small RNA libraries are uploaded in the GEO database (accession number GSE99455).
miRNA expression analysis using miQPCR
For specific amplification of miRNAs represented in isolated RNA, a small RNA-specific reverse transcription method was applied, followed by miQPCR as described by Benes et al. 15 Primers were either designed manually or downloaded from the list of miQPCR primers, 15 validated, and optimized for our samples according to the MIQE Guidelines. 16 The sequences of validated primers are summarized in Table S2 . An automatic pipetting system, Tecan Freedom EVO 150 (Tecan, Switzerland), served to prepare miQPCR reactions in 384-well plates. The expression analysis of the selected miRNAs was performed on the QuantStudio 12K Flex Real-Time PCR System (Applied Biosystems/Thermo Fisher Scientific), using a SensiFast HI-ROX kit (Bioline). The protocol used for amplification was 95°C for 5 min, followed by 45 cycles of 95°C for 10 s, 60-65°C for 10 s, and 72°C for 10 s. Cycle threshold (Ct) values for individual miRNAs were defined using the Baseline Threshold algorithm performed by QuantStudio 12K Flex software. Ct values ranged from 20 to 32, and values > 32 were considered background noise. miRNA expression levels were determined in tissue samples from all 33 mTLE+HS patients and nine postmortem controls in four technical replicates. The relative transcription of the studied miRNAs was calculated from Ct values using the 2 ÀDDCT method previously described by Livak and Schmittgen. 17 An endogenous control, RNU6B, was used for normalization. To compare miRNA levels between patients and controls, the Mann-Whitney U test without multiple comparison adjustment was performed. miRNAs with p < 0.05 were considered statistically significant.
In silico miRNA target prediction
A Target Search tool (http://mirdb.org/cgi-bin/search.c gi) was used to generate the list of target genes regulated by the newly identified miRNAs with differential expression in mTLE+HS. Pathways significantly enriched with genes targeted by aberrantly expressed miRNAs were established by the Union algorithm of DIANA-mirPath software. DIANAmiRPath performs miRNA pathway analysis, providing accurate statistics, while being able to accommodate advanced pipelines. miRPath can utilize predicted miRNA targets provided by the DIANA-microT-CDS algorithm and/or experimentally validated miRNA interactions derived from DIANA-TarBase v6.0. 18 
Results
Whole miRNome expression profiling of hippocampal tissue
We carried out NGS to reveal miRNA expression profiles of 16 patients with mTLE+HS and eight postmortem controls (with median coverage of 10.8 million unprocessed reads per sample). After adapter trimming and mapping of miRNAs performed against miRBase v21, the miRNAs accounted for 12% of total reads (an average of 1.5 million miRNA reads per sample). The NGS platform identified 1,962 miRNA species, of which 422 miRNAs were present, with coverage of >500 reads altogether in all samples. The quality of the sequenced reads was assessed using the PHRED-like score, 19 which revealed 98.5% reads with a value > 30, representing very good quality of sequencing (Fig. S1A ). The total sum of ambiguous base content was <0.01% of all bases (Fig. S1B) .
We evaluated samples by cluster analysis and searched for miRNAs with altered expression in mTLE+HS using differential expression analyses. First, we conducted oneway hierarchical clustering analysis using Spearman correlation to verify correct segregation of patients' and control samples (Fig. S2 ) and observed that libraries of four patients (S3, S4, S9, S13) clustered together with controls. For this reason, we analyzed the read distribution in these problematic libraries ( Fig. S3 ) and did not discover a scattered read distribution, thus confirming their suitability for the following analysis. This lack of a clear segregation suggests that very few miRNAs are differentially expressed between these patients and controls and that the miRNAs are expressed at very low levels. 20 Next, we employed two differential expression analyses, namely DESeq2 and edgeR, to identify miRNAs with altered expression in mTLE+HS. Both statistical approaches were concordant in identifying differentially expressed miRNAs; however, DESeq2 identified more candidate miRNAs (67 miRNAs with p < 0.01, 40 miRNAs with p = 0.01-0.05) than edgeR (32 miRNAs with p < 0.01, 15 miRNAs with p = 0.01-0.05). Differential expression analyses revealed no gender-specific miRNA with an altered expression level in mTLE+HS. This analysis did not show a correlation between age and miRNA expression. Only miR-7110-3p was up-regulated (p = 0.028) in controls >60 years of age and removed from follow-up analyses (data not shown). Importantly, miRNAs in our data exhibit stable distribution across autopsy delay period in control samples. We did not observe any autopsy delay-related decrease in miRNA levels, suggesting that the levels of miRNAs in the samples remain highly stable and autopsy delay did not have an effect on miRNA expression in control samples ( Fig. S4A,B) . We performed additional analysis on adult male rats addressing miRNA stability during the autopsy delay period from 0 to 32 h ( Figure S5 ), and we did not observe a decrease in miRNA levels with rising autopsy delay time (Fig. S5 ). The analysis of neuron-specific and neuron-enriched miRNAs did not indicate significantly different cellular composition of hippocampus in patients and controls (Fig. S6 ).
Validation of miRNome sequencing by miQPCR
The NGS platform for miRNA sequencing (miRNASeq) has several technical disadvantages, possibly introducing technology-related bias. These include detection of false-positive data, which could be mainly caused by low target read counts or mapping errors. We reduced the false positivity by comparing miRNA-Seq results with miRNA expression profiles obtained by analyzing the same cohort using miQPCR (a quantitative real-time polymerase chain reaction [qRT-PCR] method for miRNA quantification). miQPCR was used to evaluate miRNA expression in a subset selected according to NGS expression data and literature. [21] [22] [23] [24] This subset contained 39 miRNAs chosen according to the following criteria: (1) total read counts > 500 across all samples, (2) p < 0.01 in DESeq2, and (3) expression fold-change > 1.4 (Fig. 1) . We added three miRNAs to this subset that were significant in the edgeR analysis but not in DESeq2; eight miRNAs with p = 0.01-0.05 in DESeq2 analysis with predicted targets associated with epilepsy; and 11 miRNAs previously associated with epilepsy that were not significant in our miRNA-Seq analysis. Thus, the total number of miRNAs selected for further analyses was 61 (Table S3 ).
In the technical validation step, we optimized miQPCR primers for the selected miRNAs (following the MIQE Guidelines 16 ). Validation of four primers was not possible because of their high guanine-cytosine content and their sequence resemblance with other abundant miRNAs. Additionally, 13 miRNAs were excluded due to their high Ct values (>34), exceeding the reliable range of qRT-PCR. Altogether, we confirmed the expression profile of 30 miRNAs (Table 1) including "nonsignificant" miRNAs selected from literature.
To evaluate the concordance between NGS and miQPCR platforms, we compared the miRNA fold-changes assessed by both platforms in individual samples and visualized their global expression levels ( Fig. 2A) . 25 The low concentration of measured miRNAs, which were close to the detection limit of the miQPCR method, might have introduced instrument error, affecting Ct values and fold-changes in some measurements. Although these measurements were out of Figure 1 . Heatmap, showing the visualization of expression and clustering analyses of selected miRNAs. The heatmap shows the expression of 39 miRNAs, which were selected according to their altered transcription in mesial temporal lobe epilepsy with hippocampal sclerosis mTLE+HS, identified by miRNA sequencing. Each row represents an miRNA, and each column represents a sample from patients and controls. The expression was calculated as the difference between normalized read counts and the median of normalized read counts of the controls. These values were then transformed into log10 scale. Red and blue denote expression above and below the median of controls, respectively. Additionally, the heatmap depicts the result of two-way hierarchical miRNA and sample clustering calculated based on the differential expression analysis. The miRNA clustering dendrogram is shown on the left and reveals clustered miRNAs with similar regulation of expression. The sample clustering dendrogram is shown on the top and reveals that control and patients samples were segregated into separate groups. Epilepsia the optimal trend, the graphical fold-change comparison of both platforms overall resulted in good correlation (Fig. 2B) .
To confirm the expression pattern of all miRNAs used for technical validation (selected from miRNA-Seq and literature), we conducted miQPCR expression analysis on the validation cohort of an additional 17 mTLE+HS brain tissue samples (Table 1 ). This analysis validated the expression of 26 miRNAs, whereas miR-184, miR-6131, and miR-19b-3p with altered expression identified by miRNA-Seq and verified by technical validation were not confirmed in the validation cohort. Conversely, miR-134-5p showed an altered expression level only in the validation cohort. miR-193a-5p, miR-320e, and miR-490-3p, already reported in literature, were identified by miQPCR as up-regulated in both cohorts of patients with a fold-change of 1.7 and higher (p < 0.01), despite not manifesting an altered expression in miRNA-Seq.
Differential miRNA expression in mTLE+HS hippocampus
Taken together, our stringent analysis has confirmed the expression trends for 26 miRNAs. Twenty miRNAs displayed an altered expression pattern in mTLE+HS, 19 upregulated and 1 down-regulated in patients' hippocampus (Table 1) . A differential expression fold-change of 1.8 or higher was observed by both NGS and miQPCR in nine miRNAs newly associated with epilepsy (Fig. 3) . In six miRNAs selected from literature, we did not detect a significant change in expression between patients and controls (except for miR-132-p and miR-301a-3p, which were significant only in DESeq2).
Prediction of miRNA targets and pathway analysis
Using an miRNA target search tool (mirDB), we generated a list of potential miRNA target genes newly identified List of 30 miRNAs confirmed by technical validation. Twenty significantly differentially expressed miRNAs were confirmed by both NGS (DESeq2 or edgeR analysis) and miQPCR on both cohorts with a fold-change of 1.4 or higher (bold). Three miRNAs were identified as differentially expressed by NGS and validated by miQPCR in the same cohort. Seven miRNAs were chosen for analysis according to published data. Literature: 0, newly identified in epilepsy; 1, consistent with literature; À1, published results not confirmed. miQPCR, miRNA-specific quantitative real-time polymerase chain reaction; mTLE+HS, mesial temporal lobe epilepsy with hippocampal sclerosis; NA, undetermined, down-regulated in mTLE+HS; NGS, next generation sequencing. Table 2 displays the target gene pool with a target score > 90 related to neuronal function (with potential implications in epilepsy).
We employed the DIANA-mirPath v3 tool to identify potential targets of aberrantly expressed miRNAs and affected pathways. 18 This software found several dozen pathways potentially affected by miRNAs identified as having altered expression in mTLE+HS (Table S4 ). The majority of affected genes are related to molecular signaling (Wnt-, ErbB-, p53, mTOR, PI3-Akt, MAPK-, etc.) and cancer-related pathways (lung, pancreatic, colorectal, prostate, melanoma). Additionally, several pathways (axon guidance, neurotrophin signaling pathways, c-aminobutyric acidergic (GABAergic) synapse, sphingolipid signaling pathway, and SNARE interactions in vesicular transport), previously associated with epilepsy and neuronal function or brain development, were proposed as targets of nine or more differentially expressed miRNAs (p < 0.05; Table 3 ).
Discussion
This study builds upon growing evidence indicating that miRNAs fundamentally contribute to seizure and epilepsy pathophysiology. 7 The uniqueness of this study is in the complete evaluation of the whole human hippocampal miRNome using NGS to identify miRNAs potentially participating in mTLE+HS pathology on the largest cohort of patients (n = 33) yet analyzed. We employed technically independent platforms (NGS and miQPCR) to identify and quantify miRNAs, resulting in the discovery of novel miRNAs with altered expression in mTLE+HS. Multiple miRNAs widely studied in epilepsy (e.g., miR-146a, miR-132-3p, miR-132-5p, miR-134-5p) [21] [22] [23] did not manifest changes in expression levels in our patients, which implies a unique miRNA hippocampus profile in mTLE+HS, as was shown previously by Kan et al. 6 Although these miRNAs were not detected as differentially expressed in mTLE+HS, the miRNAs identified with altered expression in mTLE+HS patients in our study were in concordance with published data on these miRNAs in epilepsy. 7 We explored potential mRNA targets and biological pathways affected by discovered miRNAs using in silico analysis and found several candidates whose aberrant expression might be involved in mTLE+HS pathology. We also surveyed the concordance of miRNA-Seq and miQPCR results in evaluation of miRNAs in epileptic brain tissues.
Sequencing allows the complete evaluation of all small RNAs, with no primer bias or need for species annotation. Literature implies drawbacks in small RNA sequencing and recommends verifying obtained results by additional methods. For this reason, we compared the miRNA-Seq results with miQPCR, which is an innovative method to quantify miRNAs utilizing qRT-PCR. 15 The cross-comparison of differential expression analyses between these methods reported variations among measurements within a fold- change range < 1.4. These measurements are assigned to miRNAs without altered expression or represent biological variation. The variability is also caused by miRNAs with a low copy number in samples, which could increase instrument error. Additionally, the low miRNA concentration in samples might influence miQPCR measurements, resulting in a lower fold-change than NGS analysis. Overall, inconsistency between qRT-PCR and small RNA sequencing platforms has previously been studied. Although it is generally believed that for high-quality specimens intraplatform variability is usually minimal, cross-platform comparisons do not necessarily correlate absolutely. 20 The incomplete concordance between these two platforms might result from their different sensitivity introduced by the preamplification step included in the NGS pipeline, which is not present in miQPCR. The preamplification and more relaxed mapping parameters (two mismatches were allowed per one read 10 ) could have introduced a bias leading to false-positive miRNA detection. Moreover, fold-change comparison (Fig. 2B) showed a strong overall correlation between both methods, with only few discrepancies. Applying two different approaches to miRNA profiling increased the selectivity of the analysis and reliability of the results.
In addition to NGS analysis conducted on 24 individuals and verified in technical validation, we also confirmed the results on an additional cohort of 17 mTLE+HS patients' samples. This validation cohort proved the same expression pattern of 26 miRNAs validated in the technical validation. The up-regulation of miR-129-1-3p, miR-129-2-3p, miR193b-3p, miR-195-5p, miR-374b-5p, and miR-451a is consistent with previous studies performed on epileptic patients with mTLE+HS or other epilepsy subtypes (Table S5) . 6, 7, 27 We also discovered up-regulated miRNAs (miR-142-3p, miR-142-5p, miR-144-5p, miR-150-5p, and miR-874-3p) that have been studied with the same results only in rodent models so far. 7, 28 Our list includes miRNAs associated with other neuropathologies: Alzheimer's disease (miR-142-3p, miR-142-5p, and miR-191-5p), 29 Parkinson's disease (miR-339-5p), 30 stroke (miR-1275), 31 and brain injuries (miR-144-5p). 32 Furthermore, we identified several miRNAs (miR-1260a, miR-1260b, miR-4443, miR-4454, miR-4792, and miR-6087) that have not previously been associated Relative expression analysis of newly identified miRNAs with altered expression performed by miRNA-specific quantitative real-time polymerase chain reaction (miQPCR). The relative expression was determined among controls (Control), the technical validation cohort (Cohort 1), and the validation cohort (Cohort 2) using the miQPCR platform, and each dot represents the average of four technical replicates per sample. The red lines indicate the median relative expression. The significance of different expression levels was computed using Mann-Whitney test comparing controls and the technical validation cohort or validation cohort, and probability values are displayed above the groups. Epilepsia ILAE with neurological diseases, but their altered regulation has been observed in cancer, embryonic cells, et cetera. Moreover, miRNA 451a was previously detected specifically enriched in neurons; miR-142-3p, miR-142-5p, and miR-150-5p are enriched in microglia and miR-193 in astrocytes. 33 All aforementioned miRNAs might serve as targets for new therapeutics or could identify affected pathways leading to mTLE+HS formation. The in silico analysis showed that these miRNAs occur in a wide range of pathways and diseases; however, their causality in mTLE+HS is not yet clear and needs to be confirmed by additional functional analyses.
A subset of six miRNAs (miR-146a-5p, miR-132-5p, miR-16-5p, miR-301a-3p, miR-138-2-3p, and miR-138-5p), which were observed without aberrant regulation in our mTLE+HS samples by both approaches, were previously reported with differential expression in epilepsy. [21] [22] [23] [24] The variations in miRNA profiles might be induced by differences in technical approach (e.g., sample preparation), sample type (e.g., tissue), studied organism (e.g., rodent), and epilepsy subtype investigated in different studies. In this study, the hippocampal samples were stored as FFPE blocks, which enable easy handling, long-term cheap storage, and simpler access to samples, but the paraffin embedding process can fragment mRNAs; however, this sample processing does not affect the miRNA quality and quantity. 34 We focused on a specific epileptic subtype, mTLE+HS, which alters cell composition compared to nonsclerosis or surrounding brain tissue, and causes alterations in the miRNA profiles. 6 In addition, it is known that model organisms have slightly different expression profiles from humans, hence miRNA levels in rodent models of epilepsy might differ from those identified in epileptic patients. 35 Moreover, in the majority of published studies, the miRNA profiles were analyzed by means of predetermined profiling assays (TaqMan assay, Exiqon assays, microarrays, etc.), which are limited by selected primers/probes and prone to misinterpret miRNA isomers. All miRNA profiling platforms (NGS, qRT-PCR, microarrays, etc.) have a limited ability to detect and quantify all miRNAs participating in the disease. 8 As a result, differences observed in miRNA-Seq and miQPCR analyses emphasize the necessity of an additional quantitative method to verify every Neuron-specific, excitability-related, and neuronal function-influencing genes regulated by miRNAs newly identified with altered expression in mesial temporal lobe epilepsy with hippocampal sclerosis. miRNA targets were generated by Target Search tool (http://mirdb.org/cgi-bin/search.cgi) with a target score > 90, except as indicated.
a Target score >85.
Epilepsia, 58 (10) platform's outcomes due to their limitations, leading to false-positive or false-negative detection. Despite the technical strength, it is theoretically possible that some miRNAs were dysregulated with low fold-change only in particular hippocampal subregion(s) that might be overshadowed by nonaltered expression in other subregions. A detailed list of predicted pathways (and respective genes) affected by identified miRNAs with altered expression in mTLE+HS, which were previously associated with epilepsy. The list was generated by submitting the list of differentially expressed miRNAs to the DIANA-mirPath database. miRNA targets from the downstream part of the listed pathways (not shown) were comprised mainly of kinases, G-proteins, and cell cycle regulation signal molecules.
GABAergic, c-aminobutyric acidergic; mTLE+HS, mesial temporal lobe epilepsy with hippocampal sclerosis.
Such miRNAs would be identified in our analysis as nonsignificant. Because the expression of genes depends on the fine balance of miRNAs present in the cell, an abnormal upor down-regulation of specific miRNAs might influence genes and pathways, resulting in pathology. We applied combinatorial analyses and prediction software, namely miRDB and mirPath, to reveal a series of predicted genes and pathways that are targeted by the miRNAs altered in mTLE+HS.
miRDB identified a series of potential mRNA targets affected by miRNAs newly discovered to have altered expression in mTLE+HS patients ( Table 2 ). Four of these nine miRNAs potentially inhibit the gene expression of potassium K + channels, their subunits, and interacting proteins, thus supporting the prevailing potassium (K + ) hypothesis of epilepsy origin. 36 Additionally, mirPath software has shown that 11 of 20 miRNAs with altered expression potentially affect the GABA pathway, another widely accepted hypothesis of epilepsy origin and ictogenesis. 36 The GABAergic synaptic pathway represents the most abundant inhibitory neurotransmission in the mammalian central nervous system and has previously been associated with epilepsy in multiple studies (reviewed in DiNuzzo et al. 36 ). mirPath software has also identified several dozen pathways (e.g., signaling, cancer, etc.) potentially influenced by differentially expressed miRNAs (Table S4) . Table 3 contains a subset of pathways previously associated with neuronal function and epilepsy . Axon guidance represents a key stage in the formation of neuronal networks and guides axons in various factors (e.g., netrins, semaphorins) affecting the cytoskeletal organization. The inaccuracy in axon targeting might result in a severe malfunction of newly formed neuronal connections such as mossy fiber sprouting in epileptic hippocampus, facilitated by down-regulation of semaphorin 3A. 37 In close relationship with axon guidance is neurotrophin signaling, which uses a family of trophic factors (neurotrophins) to govern the differentiation, survival, and remodeling of neural cells with a possible effect on excitability. 38 Sphingolipid signaling and SNARE interactions in vesicular transport facilitate the intracellular trafficking processes essential for different biological events including neuronal network development and maintenance, and their imbalance could result in serious neurological disorders (e.g., schizophrenia, Alzheimer disease, epilepsy). 39, 40 All aforementioned pathways have been previously studied in connection with mTLE+HS and/or other subtypes of epilepsy. However, these in silico analyses need to be confirmed by further functional experiments on cell cultures and animal models.
Taken together, we evaluated the miRNA composition in hippocampal tissue samples from patients with mTLE+HS (n = 33) and postmortem controls (n = 9) using miRNA-Seq and miQPCR platforms. To our knowledge, our miRNA profiling was performed on the largest cohort of patients with mTLE+HS so far. We sequenced individual samples and identified >100 miRNAs with altered expression in patients. Our validation analyses on two cohorts of patients discovered the up-regulation of 11 miRNAs published in previous studies and found that six miRNAs commonly associated with epilepsy are not aberrantly expressed in mTLE+HS. We discovered nine miRNAs potentially related to mTLE+HS that have not yet been associated with epilepsy. Additionally, in silico analyses of these miRNAs revealed that they could target genes and pathways associated with neuron adhesion, ion channels, or synaptic vesicle trafficking and their disruption could be implicated in the induction of mTLE+HS or other subtypes of epilepsy. Although this study was focused on patients with HS, a prospective comparative analysis of patients with and without HS might provide novel insight into the pathology of epilepsy. Finally, further investigation of aberrantly expressed miRNAs and their relevant targets might lead to an improved understanding and treatment of epilepsy.
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